About this trial
moraxella catarrhalis is responsible for respiratory tract infection in children and adults with streptococcus pneumonia and haemophilus influenza.Moraxella catarrhalis is gram negative diplococci, non-motile and non spore bearing bacteria. Until, 1995 it was considered as a non pathogenic respiratory tract flora.This bacteria is an important pathogen and a common cause of both upper and lower respiratory tract infections, pneumonia, sinusitis and conjunctivitis in infants, children and in elderly patients. In adults, M. catarrhalis also causes chronic obstructive pulmonary disease (COPD) and pneumonia. However, it is associated with a number of respiratory infections affecting both children and adults, including laryngitis, bronchitis and pneumonia .
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
all children with bacterial pneumonia
Disqualifiers
viral pneumonia , tuberculosis and immunocompromised
Trial population
children with respiratory tract infection
Trial design
Case-only
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
isolation of moraxella catarrhalis
isolation of organism on muller hinton agar
Secondary outcomes
detection of virulence genes of moraxella catarrhalis
detection of virulence genes by PCR
detetion of antibiotic resistance
detetion of antibiotic resistance by agar disc diffusion
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: